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Abstract
Background: Rare germlinemutations in DNA repair genes are associated with prostate
cancer (PCa) predisposition and prognosis.
Objective: To quantify the frequency of germline DNA repair gene mutations in UK PCa
cases and controls, in order to more comprehensively evaluate the contribution of
individual genes to overall PCa risk and likelihood of aggressive disease.
Design, setting, and participants: We sequenced 167DNA repair and eight PCa candidate
genes in a UK-based cohort of 1281 young-onset PCa cases (diagnosed at 60 yr) and
1160 selected controls.
Outcome measurements and statistical analysis: Gene-level SKAT-O and gene-set
adaptive combination of p values (ADA) analyses were performed separately for cases
versus controls, and aggressive (Gleason score 8, n = 201) versus nonaggressive
(Gleason score 7, n = 1048) cases.
Results and limitations: We identified 233 unique protein truncating variants (PTVs)
with minor allele frequency <0.5% in controls in 97 genes. The total proportion of PTV
carriers was higher in cases than in controls (15% vs 12%, odds ratio [OR] = 1.29,
95% confidence interval [CI] 1.01–1.64, p = 0.036). Gene-level analyses selected NBN
(pSKAT-O = 2.4  104 [24_TD$DIFF]) for overall risk and XPC (pSKAT-O = 1.6  104) for aggressive disease,
both at candidate-level significance (p < 3.1 104 and p < 3.4  104, respectively).
Gene-set analysis identified a subset of 20 genes associated with increased PCa risk
(OR = 3.2, 95% CI 2.1–4.8, pADA = 4.1 103) and four genes that increased risk of
aggressive disease (OR = 11.2, 95% CI 4.6–27.7, pADA = 5.6  103), three of which overlap
enethe predisposition gy These authors are joint last authors.
* Corresponding author. The Institute of Cancer Research, 15 Cotswold [32_TD$DIFF]Road, Sutton [33_TD$DIFF], SM2 5NG, UK.
Tel. +44 208 [34_TD$DIFF]7224534.
ote-jarai@icr.ac.uk (Z. Kote-Jarai).E-mail address: zsofia.khttps://doi.org/10.1016/j.eururo.2019.01.050
0302-2838/© 2019 The Authors. Published by Elsevier B.V. on behalf of Euro
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).set.pean Association of Urology. This is an open access article
Conclusions: The union of the gene-level and gene-set-level analyses identified
23 unique DNA repair genes associated with PCa predisposition or risk of aggressive
disease. These findings will help facilitate the development of a PCa-specific se-
quencing panel with both predictive and prognostic potential.
Patient summary: This large sequencing study assessed the rate of inherited DNA
repair gene mutations between prostate cancer patients and disease-free men. A
panel of 23 genes was identified, which may improve risk prediction or treatment
pathways in future clinical practice.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).
Table 1 – Summary of study cohort characteristics
Clinical variable Cases (n = 1281) Controls (n = 1160)
Age of diagnosis (cases) or blood draw (controls)
Median 57 56
Quartiles 54–58 53–59
Range 38–60 44–67
Unknown (count) 0 (0%) 637 (55%)
Ethnicity
European ancestry 1281 (100%) 1160 (100%)
Diagnosis method
Clinical symptoms 739 (58%) –
Screen detected 403 (31%) –
Unknown 139 (11%) –
PCa family history
0 973 (76%) 510 (44%)
1 207 (16%) 17 (1.5%)
2 40 (3.1%)) 1 (0.1%)
3+ 5 (0.4%) –
Unknown 56 (4.4%) 632 (54%)
PSA at diagnosis (ng/ml)
Median 8.4 –
Quartiles 5.6–18.3 –
Range 0.04–9020 –
Unknown (count) 43 (3.4%) –
Gleason score (highest recorded)
6 576 –
7 472 –
8 201 –
Unknown 32 –
Primary tumour stage at diagnosis
T1 365 (28%) –
T2 524 (41%) –
T3 295 (23%) –
T4 63 (4.9%) –
TX 34 (2.7%) –
Lymph node status at diagnosis
N0 787 (61%) –
N1 89 (6.9%) –
NX 405 (32%) –
Distant metastases at diagnosis
M0 757 (59%) –
M1 92 (7.2%) –
MX 432 (34%) –
PCa = prostate cancer; PSA = prostate-specific antigen.
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Prostate cancer (PCa) is the most common solid tumour in
men living in the developed world besides nonmelanoma
skin cancer and responsible for over 300 000 deaths per
year worldwide [1], although the majority of PCa cases are
diagnosed with low- or intermediate-risk disease. Family
history (FH) is a strong risk factor for PCa, and twin studies
demonstrate a large contribution by heritable genetic
factors [2]. Increasing evidence indicates that both common
and rare germline variation contribute to PCa predisposition
[3,4]. Rare loss of function (LoF) germline mutations in
BRCA2 have convincingly been implicated as contributing to
both FH of PCa and increased likelihood of aggressive
disease with poor prognosis, whilst lower mutational
frequencies or less consistent evidence has also been
presented for a small subset of additional DNA repair genes
including ATM, BRCA1, BRIP1, CHEK2, GEN1, MSH2, NBN,
PALB2 and RAD51D[4_TD$DIFF] [5–7].
In this study, we performed screening of 167 genes from
DNA damage response and repair pathways within a large
UK-based case–control cohort with long follow-up, to
further investigate the role of germline DNA repair gene
mutations in PCa predisposition, clinical outcome, and
survival. To maximise the power in this study, we utilised
young-onset cases (diagnosed at 60 yr) and control
samples screened for either no PCa FH or low prostate-
specific antigen (PSA; <0.5 ng/ml). These results should
help inform the composition of future gene panels for
clinical screening and risk profiling.
2. Patients and methods
2.1. Study population
Self-reported European ancestry PCa cases were randomly selected from
the young-onset (diagnosed at 60 yr) subcohort of the UK Genetic
Prostate Cancer Study (UKGPCS) [8]. Control menwith no FH of PCawere
recruited from GP practices participating in UKGPCS, or those with PSA
<0.5 ng/ml were recruited from the Prostate Testing for Cancer and
Treatment (ProtecT) trial [9]. Cases and controls were matched for
genetic ancestry, with ethnicity confirmed for all samples by principal
component analysis and analyses restricted to genetically European
ancestry individuals (Supplementary material, Methods, and Supple-
mentary Figs. [36_TD$DIFF]1 and [37_TD$DIFF]2). No formal matching by age was performed,
although the age profiles of the case cohort and control menwith known
age at recruitment were broadly similar (Table 1). All studies were
approved by the appropriate ethics committees (UKGPCS 848). All
participants gave written informed consent.Analyses were performed comparing all post-quality control (QC)
PCa cases (n = 1281) versus controls (n = 1160), and for case–case
comparisons of aggressive (Gleason score 8, n = 201) versus nonag-
gressive (Gleason score 7, n = 1048) cases (Table 1).
2.2. Target genes
We constructed a 175 gene sequencing panel after a literature review of
DNA repair, damage response and cell cycle pathways, and databases
(Supplementary material, Methods). The panel comprised 107 genes in
Table 2 – Summary of gene panel composition by primary DNA
repair pathway
Consensus pathway Total number of genes
Direct reversal repair (DRR) 3
Base excision repair (BER) 25
Mismatch repair (MMR) 12
Nucleotide excision repair (NER) 30
Homologous recombination (HR) 26
Nonhomologous end joining (NHEJ) 11
Fanconi anaemia (FA) 19
DNA damage response (DDR) 22
Cell cycle regulation 19
PCa candidates 8
Total 175
PCa = prostate cancer.
E U RO P E AN U RO L OGY 76 ( 2 019 ) 3 2 9 – 3 37 331DNA repair pathways, 60 DNA damage response and cell cycle regulation
genes, and eight other candidate PCa predisposition genes (HOXB13,
MSR1, RNASEL, AR, ESR1, ESR2, NKX3-1, and SPOP; Table 2 and
Supplementary Table 1).
2.3. Target capture and sequencing
A custom SureSelect XT bait library (Agilent Technologies, Santa Clara, CA,
USA)wasdesigned forcoding[5_TD$DIFF] regionsof the175 target genes.DNA libraries
were prepared using an automated in-house sample preparation protocol
(Supplementary material, Methods) and captured libraries sequenced
using Illumina HiSeq 2000 v4 chemistry (Illumina, San Diego, CA, USA).
2.4. Sequence data analysis, variant annotation, and QC
Raw sequencing reads were aligned to GRCh37 using BWA 0.5.8
[10]. Samples reaching 80% of the target at 10 read depth as defined
by Picard v.1.52 (http://broadinstitute.github.io/picard/) and contamina-
tion <3% as estimated by verifyBamID v1.1.1 (https://github.com/statgen/
verifyBamID/releases) were genotyped using GATK v2.8-1 [11]. Per-gene
coverage levelswereassessedusing theGATKtool “DiagnoseTargets”,with
a per-base coverageQC threshold set at8 reads at base quality20. Low-
quality genotypes were removed according to established thresholds
(Supplementary material, Methods) [12–14]. Standard QC procedures
were applied to remove poorly performing samples and variants
[15]. These include variant-level filters such as heterozygosity and
missingness[38_TD$DIFF] (Supplementary Fig. 3), and sample-level filters including
relatedness and divergent ancestry (Supplementary material, Methods).
Owing to the targeted nature of the sequencing data, ancestry QC was
augmented with additional QC data from the OncoArray platform [16].
Variants were annotated by wANNOVAR [17] using RefSeq Gene
definitions [18], and variant consequence was checked using Variant
Effect Predictor (VEP; release 84, March 2016) [19]. Protein truncating
variants (PTVs; frameshift Indels, stop gain, and splice variants) were
also annotated with the VEP plugin Loss-of-Function Transcript Effect
Estimator (LOFTEE; https://github.com/konradjk/loftee/), and Indels in
splice sites were manually reviewed for consequence. For further
analysis, variants were categorised into two groups: (1) tier 1 contained
all high-confidence PTVs according to LOFTEE and manual splice-site
review and (2) tier 2 contained all remaining variants with Combined
Annotation Dependent Depletion (CADD) v1.3 score >20 [20].
2.5. PCa susceptibility gene identification
Comparisons of rare PTV frequencies between our cohort and previous
publications were restricted to tier 1 mutations with minor allelefrequency (MAF) <0.5% in our controls. For novel gene discovery tests,
due to the low frequencies of individual variants in this study, we
performed two distinct aggregate statistical tests for each study
phenotype: (1) a gene-level SNP-set association test over all genes
containing two or more tier 1 or 2 variants and (2) a gene-set-level
association test where tier 1mutations withMAF<0.5% in controls were
collapsed per gene.
To identify associated genes (test 1) we used SKAT-O, a unified test
able to tolerate the inclusion of neutral variants or variants with
opposing direction of effect, which finds the optimal combination
between burden and kernel tests for the tested data [21]. [39_TD$DIFF]SKAT-O [40_TD$DIFF]was [41_TD$DIFF]run
unadjusted over genes containing two or more variants (tier 1 or tier 2),
with statistical significance set at a Bonferroni adjusted p value of
a = 0.05/number of genes; p < 3.1 104 [35_TD$DIFF] for case/control analysis
(159 genes), and p < 3.4  104 for aggressive phenotype analysis
(146 genes). To further investigate gene-level SKAT-O association signals,
we used adaptive combination of p values (ADA), a “combination of
p values” method that adaptively truncates p values with an optimal
threshold for the tested data set, removing neutral variants and
identifying the likely underlying variant-level components of the
gene-level signal [22]. Gene-level ADA for genes identified by SKAT-O
was run using all tier 1 and 2 variants within these genes and default
settings (corresponding to p value truncation thresholds of 0.1–0.2
considered in 0.01 increments) except for increasing to 10 000
permutations and using the mid p value setting [23].
We subsequently performed an additional gene discovery analysis
(test 2) in which ADA was used to identify a candidate gene set rather
than individual variants, by collapsing tier 1 mutations with MAF <0.5%
in controls on a per-gene basis rather than a variant-level basis (except
for CHEK2 where 1100delC was a separated from all other CHEK2 PTVs
due to its relatively higher frequency), under the assumption that rare
tier 1 variants aremore likely to confer a homogenous effect within each
gene. For each phenotype, gene-set-level ADA was run with default
settings except for mode = “dominant”, twoSided = F, midp = TRUE, and
10 000 permutations. We report both the permuted p value (PADA) and
the truncation threshold (opt.t). To display the resulting gene set selected
by ADA, forest plots were constructed showing gene-level adjusted odds
ratios ([43_TD$DIFF]ORs) calculated from the collapsed tier 1MAF<0.5% variant count
using unadjusted Firth's regression.
2.6. Survival analysis
Survival analyses were performedwithin the PCa case cohort to examine
the effect of gene set's carrier status on patient outcome. The follow-up
period was based on the date of diagnosis, date of consent into the
UKGPCS, and date of last follow-up. Cases were diagnosed and came
under observation at the date of consent. Survival timewas calculated as
the difference in time between age of diagnosis and the last recorded
follow-up or date of death.
Kaplan-Meier survival analysis and univariable Cox regression
models, adjusted for age, were performed. Log-rank tests were
performed to investigate the equality of survivor functions across
gene sets. Multivariable Cox regression models of gene set carrier status
were constructed, adjusted for age and all covariates significant at
p < 0.05 under Cox univariate regression. All survival analyses were
performed in Stata 14.2 [24].
3. Results
3.1. Sequencing and sample summary
After QC, variant data were available for 1281 PCa cases and
1160 control samples. Of 175 genes targeted, three (GTF2H2,
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resulting from segmental duplication and one (PRKDC) was
removed as wANNOVAR was unable to annotate coding
consequences due to an incomplete RefSeq gene definition
(Supplementary Fig. [44_TD$DIFF] and Supplementary Table 2). From
the 171 tractable target genes, we classified 2078 variants in
164 genes as tier 1 or 2 (Supplementary Table 3).
3.2. Known gene-set enrichment
A total of 233 PTVs with MAF <0.5% in controls were
identified in 97 of the genes passing QC. Overall PTV carrier
burden was significantly enriched in PCa cases compared
with controls (15% vs 12%; p = 0.036). This enrichment was
greater within the BROCA panel of cancer predisposition
genes, primarily focussed on hormone-driven breast and
ovarian cancers (http://web.labmed.washington.edu/tests/
genetics/BROCA_VERSIONS) [25]. For the original 22 gene
BROCA panel, 57 PTVs were identified in 15 genes (4.5% in
cases vs 2.2% in controls; p = 2.5  103[42_TD$DIFF]), whilst for the
current [45_TD$DIFF]BROCA-[46_TD$DIFF]v7 containing 66 genes, 80 PTVs were
identified in 23 genes (5.5% in cases vs 3.5% in controls;
p = 0.020). The greatest enrichment was for the top five
genes reported by Pritchard et al. [7] (ATM, BRCA1, BRCA2,
CHEK2, and GEN1), with 38 total PTVs identified across all
five genes (3.8% vs 1.4%; p = 2.1 104).
3.3. Gene-level association
Gene-level analyseswere restricted to genes containing two
or more tier 1 and 2 variants. In the case/control analysis
(159 genes tested)NBN reached significance (p = 2.4  104;
p = 0.18 for aggressiveness), as did XPC for the aggressive
phenotype (146 genes tested; p = 1.6  104, p = 0.90 for
overall PCa; Fig. 1, and Supplementary Figs. 5 and [48_TD$DIFF]6). In
addition, HOXB13 (p = 1.1 103[47_TD$DIFF]; p = 0.12 for aggres-
siveness) and POLL (p = 9.1 104; p = 0.11 for aggres-
siveness) demonstrated nominal significance (p < 0.05) in
the case/control analysis.
[(Fig._1)TD$FIG]
Fig. 1 – SKAT-O results for (A) case–control and (B) aggressive phenotypes. The
significance threshold for each phenotype, according to the number of genes c
(159 and [9_TD$DIFF]146 respectively[10_TD$DIFF]). [11_TD$DIFF]Genes are labelled at p < [12_TD$DIFF]0.05. PTV = protein truncatTo further investigate these SKAT-O association signals,
we used ADA to interrogate the combination of variants
contributing to the association (HOXB13 and POLLwere also
included due to the well-characterised role of HOXB13 in
PCa predisposition). For both NBN and HOXB13, ADA
identified a single-recurrent heterozygous nonsynonymous
variant enriched among PCa cases to be responsible for the
gene-level signal, whilst for POLL, four of the 15 tested
variants were identified to be responsible for potentially
modulating risk (three protective and one pathogenic). For
XPC, ADA selected six singleton heterozygous variants from
the nine variants tested as contributing to the aggressive
phenotype, all of which were observed in different
individuals (Table 3).
3.4. Candidate gene-set discovery
For the case/control phenotype, ADA selected 20 distinct
genes containing rare heterozygous PTVs from a panel of
57 genes (both categories of CHEK2 PTV selected). These
genes were significantly enriched among PCa cases
compared with controls (8.5% vs 2.8%, OR = 3.2, 95%
confidence interval [CI] 2.1–4.8, pADA = 4.1 103, opt.
t = 0.2; Fig. 2A), and eight patients were carriers of more
than one PTV (Supplementary Table 4). Only five of these
genes (ATM, BRCA1, BRCA2, CHEK2, and MSH2) overlap the
BROCA 22 gene set. In the aggressive phenotype analysis,
out of 35 genes, ADA selected four that were significantly
enriched in Gleason 8 cases in comparison with Gleason
7 patients (8.0% vs 0.8%, OR = 11.2, 95% CI 4.6–27.7,
pADA = 5.6  103, opt.t = 0.1; Fig. 2B). Three of these genes
overlap with the case/control gene set (BRCA2, CHEK2, and
MSH2), whilst ERCC2 is unique to the aggressive set. In
contrast to other CHEK2 PTVs, the CHEK2 1100delC variant
was not enriched among aggressive cases.
The combined set of 21 genes identified in these analyses
demonstrated a continuum of aggressive phenotype risk
(Supplementary Fig. 7), with the upper tail defining
predisposition genes with a lower risk of aggressive diseasedashed line denotes the Bonferroni-corrected candidate-level
ontaining two or more tier 1 and 2 PTVs included in the analysis
ing variant.
Table 3 – Variant-level investigation of genes nominally significant in the SKAT-O gene-level analysis of tier 1 and 2 variants
Gene (variants tested) ADA-selected variants rsID Tier Case (n = 1281) Control (n = 1160) CADD ExAC NFE Variant p value
Case–control phenotype
NBN (4) 8:90993640_C/T rs61753720 2 18 2 26.3 0.0030 4.3  104
POLL (15) 10:103339221_G/A rs555309980 2 3 0 34 0.000047 0.13
10:103339487_C/T rs200705693 2 0 2 22.3 0.000091 0.20
10:103342648_C/T rs139871590 2 1 5 34 0.0015 0.09
10:103343423_G/A rs142726673 2 0 10 23.7 0.00080 4.7  104
HOXB13 (9) 17:46805705_C/T rs138213197 2 20 3 29.6 0.0031 5.9  104
Aggressive phenotype
XPC (9) 3:14187577_G/A – 2 1 0 23.5 0.000015 0.07
3:14193884_G/A rs3731152 2 1 0 31 0.000033 0.07
3:14199634_C/G – 2 1 0 26.8 – 0.07
3:14208716_T/C rs200485886 2 1 0 24.7 0.000078 0.07
3:14209787_G/A rs188716339 2 1 0 24.2 0.000031 0.07
3:14214457_G/A – 2 1 0 22.8 – 0.07
ADA = adaptive combination of p values; NFE = non-Finnish Europeans.
The number of unique variants per gene tested, individual variants selected by ADA, case and control variant counts, variant CADD v1.3 score, minor allele
frequency in ExAC NFEs, and variant-level p values (using unadjusted Firth's logistic regression) are shown for each variant selected by ADA.
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into nonoverlapping sets of 18 genes in the predisposition
panel (Predis18) and four in the aggressive panel (Agg4),
with CHEK2 split (1100delC in Predis18 and other PTVs in
Agg4; Fig. 2C). As would be expected, given the phenotype
criteria, Agg4 carriers showed significant enrichment for
several clinical indicators of aggressive disease (higher PSA,
Gleason score, tumour stage, and nodal spread). Predis18
carriers showed no association with any clinical variable
(Table 4). A modest increase in PCa FH rate was observed
among Predis18 carriers compared with noncarriers, whilst
[(Fig._2)TD$FIG]Fig. 2 – Gene set selection. Forest plots of (A) [13_TD$DIFF]20 unique genes selected by ADA case
analysis. Odds ratios (ORs) were estimated from the collapsed tier 1 MAF <0.5% var
each count to provide estimates for genes with no carriers in one cohort. (C) [14_TD$DIFF] nters
partition into non overlapping Predis18 and Agg4[1_TD$DIFF] gene [16_TD$DIFF]panels. ADA = adaptive comPCa FH rates were lower among Agg4 carriers; however,
both these trends were nonsignificant. Suggestive but
nonsignificant increases in rates of breast and pancreatic
cancer FH were also observed for carriers of the Agg4 gene
set (Supplementary Table 5). Kaplan-Meier survival analysis
showed a significant global difference across gene-set
carriers (Agg4, Predis18, and noncarriers) for both all-cause
and PCa-specific mortality (log-rank test, pall-cause
= 9.8  108[49_TD$DIFF], pPCa-specific = 4.1 106). This is attributable
to Agg4 carriers demonstrating significantly worse survival
than noncarriers, as survival between Predis18 carriers and–control analysis and (B) four genes selected by ADA aggressive phenotype
iant count using unadjusted Firth's logistic regression, with 0.5 added to
ection of gene sets [15_TD$DIFF]from the case-control and aggressiveness analyses and
bination of p values; MAF =minor allele frequency.
Table 4 – Clinical characteristics of Predis18 and Agg4 carrier and noncarrier cases
Clinical variable Agg4 Predis18
Carriers (n = 24) Noncarriers (n = 1257) Trend Carriers (n = 87) Noncarriers (n = 1194) Trend
Age at diagnosis (yr)
Median 58 57 p = 0.14
U = 12 470
57 57 p = 0.50
U = 54 198
Quantiles 54–59 54–58 54–58 54–58
Range 47–60 38–60 43–60 38–60
PSA at diagnosis (ng/ml)
Median 29.6 8.3 p = 9.5  104
U = 8836
9.1 8.4 p = 0.57
U = 45 811
Quantiles 10.5–99.5 5.5–18 6–16.1 5.5–18.5
Range 0.41–399 0.04–9020 1.1–1151 0.04–9020
Unknown 0 43 5 38
Gleason score (highest recorded)
6 6 570 40 536
7 2 470 35 437
8 16 185 6 195
Unknown 0 32 6 26
Primary tumour stage at diagnosis
T1 1 364 18 347
T2 6 518 p = 1.1 105 40 484 p = 0.40
T3 9 286 M2 = 19 22 273 M2 = 0.70
T4 5 58 3 60
TX 3 31 4 30
Lymph node status at diagnosis
N0 13 774 54 733
N1 8 81 p = 5.6  104 8 81 p = 0.51
NX 3 402 25 380
Distant metastases at diagnosis
M0 18 739 52 705
M1 4 88 p = 0.29 3 89 p = 0.26
MX 2 430 32 400
PCa = prostate cancer; PSA = prostate-specific antigen.
Age and PSA at diagnosis, Gleason score, tumour grade, nodal spread, and metastatic statuses are shown for carrier and noncarrier PCa cases of each gene set.
Tests for enrichment between carriers and noncarriers were performed for clinical variables collected at diagnosis using Mann-Whitney U test (age and PSA),
Mantel-Haenszel test for linear-trend (tumour stage), or Fisher's exact test (nodal and metastatic spread).
E U RO P E AN URO L OGY 76 ( 2 019 ) 3 2 9 – 3 37334noncarriers was very similar. For all-cause survival (Fig. 3A),
5-yr survival rates were 60% for Agg4 (95% CI 34–79%), 93%
for Predis18 (95% CI 85–97%), and 89% for noncarriers (95%
CI 87–91%). The hazard ratio for Agg4 carriers compared
with noncarriers was 2.69 (95% CI 1.32–5.50; Fig. 3C). A
similar pattern was observed when considering only PCa-
specific survival (Fig. 3B), though hazard ratios were not
statistically significant, possibly due to the reduction in the
number of events (282 compared with 212). Five-year
survival rates were 60% for Agg4 (95% CI 34–79%), 94% for
Predis18 (95% CI 86–98%), and 91% for noncarriers (95% CI
89–92%). The hazard ratio for Agg4 carriers compared with
noncarriers was 1.83 (95% CI 0.77–4.39; Fig. 3D).4. Discussion
Direct sequencing approaches are required to investigate
the effect of rarer germline variants in complex disease
predisposition; however, to date, these studies in PCa have
generally been smaller in size, considered only a handful of
candidate genes, or lacked control cohorts. In this study, we
investigated the role of DNA repair and damage response
genes in predisposition to PCa and aggressive disease in a
case/control cohort. We focused on protein truncating (tier1) and predicted conserved (tier 2) variants using both
gene-level SKAT-O and gene-set-level ADA analyses.
Gene-level analysis of tier 1 and 2 variants identified
significant associations in NBN for PCa predisposition and
XPC for disease aggressiveness. The NBN signal was refined
by ADA to rs61753720, a G>T single nucleotide variant
(SNV) resulting in a D95N substitution. A previous study by
the ICPCG consortium found this variant at a low frequency
in both unselected (1/613) and familial (1/121) Finnish PCa
cohorts, and absent (0/440) in controls [26]. For the
association between the XPC gene and a higher Gleason
score, ADA selected multiple singleton SNVs across the
gene. Both POLL and HOXB13 were also marginally
associated with PCa predisposition in the case/control
analysis. Since the role of HOXB13 rs138213197 in PCa risk
has been well established, sample size may have been a
limiting factor in achieving Bonferroni-corrected signifi-
cance, suggesting that POLL may also warrant additional
follow-up in larger cohorts or meta-analyses of individual
studies.
Gene-set-level analysis identified 20 genes in which
PTVs were associated with PCa predisposition. These
included the established BRCA1/2 genes, a handful of
additional genes that have been indicated previously as
prospective PCa candidates (ATM, CHEK2, GEN1, MSH2, and
[(Fig._3)TD$FIG]
Fig. 3 – Gene set survival. Kaplan-Meier survival plots depicting (A) overall survival and (B) cause-specific survival. Multivariate Cox regression analysis
of phenotypic features and gene set carrier status are shown for (C) overall survival and (D) cause-specific survival. Analyses were conducted using PCa
cases only. CI = confidence interval; diag. = diagnosis; Fam. hist. = family history; Haz. ratio = hazard ratio; PCa = prostate cancer; PSA = prostate-specific
antigen; 1st deg. rels. = first-degree relatives.
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substantive evidence for a role in PCa predisposition has
been presented to date (BLM, CDC25C, ERCC3, LIG4, MSH5,
NEIL2, NHEJ1, PARP2, POLD1, POLE, POLM, RECQL4, and TDP1).
We furthermore identified four genes associated with more
aggressive PCa phenotype, three of which overlapped the
20-gene PCa predisposition set. These include BRCA2, for
which association with a more aggressive phenotype has
reliably been demonstrated [6,7,27,28], whilst we also
present evidence that carriers of PTVs in MSH2, CHEK2
(excluding 1100delC), and ERCC2 also have a substantially
higher likelihood of developing aggressive disease.
Our criteria to stratify cases for the aggressive phenotype
analysis (Gleason score7 vs8) were chosen to maximise
the homogeneity and risk of the aggressive group. Within
the Gleason 7 category, however, Gleason 4 + 3 patients
have poorer prognosis than Gleason 3 + 4 patients, with
these two subgroups categorised separately according to
the prognostic grade grouping method [29]. We therefore
compared the results of our aggressive analysis with those
of Gleason 4 + 3 cases reclassified as aggressive, equivalent
to grade group 2 versus 3 (n = 924 vs 324) instead ofgrade group 3 versus 4 used for our primary analysis.
Under this classification, ADA selected the Agg4 gene set
alongside three additional genes (ESR2, GTF2H4, and
SETMAR; pADA = 8.1 103, opt.t = 0.105). Additional com-
parisons between Gleason8 cases and controls selects the
same Agg4 genes as our primary aggressiveness analysis
(pADA = 0.014, opt.t = 0.115), whereas analysis of Gleason 7
cases versus controls selects 12 genes overlapping the
Predis18 gene set identified in the case/control analysis
(ATM, BRCA1, CDC25C, CHEK2 1100delC, GEN1, LIG4, NEIL2,
PARP2, POLD1, POLM, RECQL4, TDP1; pADA = 0.029, opt.
t = 0.12).
The overall 23-gene panel [50_TD$DIFF]from the union of our gene and
gene-set-level results for PCa susceptibility and disease
aggressiveness [51_TD$DIFF]spans a range of primary DNA repair pathways
(Supplementary Table 1), with homologous recombination,
mismatch repair, base excision repair, nucleotide excision
repair, nonhomologous end joining, and DNA damage
response all represented through multiple genes. Although
Gleason score was used to stratify aggressive and nonaggres-
sive disease and is correlated with other features indicative of
poor prognosis, among carriers of mutations in the Agg4 gene
E U RO P E AN URO L OGY 76 ( 2 019 ) 3 2 9 – 3 37336set, we nevertheless observed substantial enrichment over
noncarriers for nodal invasion (38% vs 9.5%), metastatic
disease (18% vs 11%), and reduced survival (PCa-specific 5-yr
survival rate 60% vs 91%), suggesting that these genes could
potentially demonstrate clinical utility for the identification of
individuals at a higher risk of advanced disease prior to
progression. The absence of BRCA1 and ATM from our
aggressive gene set is however notable, as PTVs in these
genes have been implicated in increased risks of metastatic
and lethalPCacancerpreviously [6,7,30].Thisdiscrepancymay
in part reflect our use of Gleason score to define aggressive
disease due to the modest proportion of patients with
metastatic disease in our unselected cohort (7.2% of overall
cohort,11%excludingunknownstatus) in comparisonwith the
more stringent metastatic or lethality indicators employed
elsewhere in cohorts enriched for these outcomes, or
alternatively that these genes confer lower influence upon
aggressiveness in younger patients. It is also noteworthy that
whilst CHEK2was associatedwith PCa predisposition for both
1100delC and other PTVs, only the non-1100delC CHEK2
variants were found to contribute towards aggressive disease
inourstudy.Thisobservation,however, contrastswitharecent
report in which only the 1100delC variant and not overall
CHEK2 mutations were enriched in lethal PCa patients [31],
and therefore requires further validation in independent
cohorts. These combined reports could, however, potentially
indicate that the downstream functional consequence of the
1100delC founder mutation may partly differ from those of
other CHEK2 PTVs in prostate tissue.
Whilst the novel genes that we have identified represent
exciting candidate moderate-penetrance PCa-risk genes,
these findings nonetheless require additional validation in
independent cohorts. In particular, we note that the optimal
p value truncation thresholds used by ADA are tuned
towards greater sensitivity than specificity to maximise
power for rare variant discovery in sequencing study
sample sizes, and no suitable replication set was available
for confirmation of our findings. Furthermore, even though
this is the largest DNA repair gene germline sequencing
study for PCa to date, our power to detect rare associations
with moderate effect sizes remained modest.
Whilstour strategyofusing screenedcontrols (noPCaFHor
PSA <0.5 ng/ml) potentially increased our power to detect
associations, this also has the potential to introduce bias in our
case/control analyses. We therefore cannot completely
exclude the possibility that the use of PSA or FH in our control
selection criteria led to an observed depletion of LoF variants
among controls; although this would imply a uniform
direction and comparatively high penetrance of effects across
a wide range of DNA repair genes and pathways[52_TD$DIFF] should these
associations [53_TD$DIFF]have been driven exclusively by extraneous
variables such as low PSA levels independently of PCa.
5. Conclusions
In this study, we confirmed previous PCa predisposition
gene reports and also present evidence for additional novel
genes. Our combined gene and gene-set-level analyses
provide evidence for a prospective screening panel of23 genes that may facilitate identification of individuals at a
higher PCa risk prior to disease onset, who would warrant
enhanced screening. In addition, PCa patients who are
carriers of mutations in these genes could potentially
benefit from personalised treatment pathways [27,32]. We
believe that these genes warrant evaluation by the wider
scientific and clinical communities in larger prospective
studies or meta-analyses. There is also a need to formally
test the ability of these genes to predict survival in an
independent cohort within aggressiveness strata.
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